相关实验视频

Updated: Aug 3, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

针对性基于的抗炎纳米剂用于增强性风湿性关节炎治疗

Ziwei Zhao¹, Hao Xiong², Jinyong Wu¹

¹Lab of Low-Dimensional Materials Chemistry, Key Laboratory for Ultrafine Materials of Ministry of Education, Frontier Science Center of the Materials Biology and Dynamic Chemistry, School of Materials Science and Engineering East China University of Science and Technology Shanghai China.

Exploration (Beijing, China)

|October 30, 2025

概括

这项研究引入了一种基于的新型纳米系统 (RuFOMs-FA) 用于类风湿性关节炎 (RA) 治疗. 它通过向M1巨细胞并恢复氧气平衡,有效地减少炎症和关节损伤.

科学领域:

生物材料科学生物材料科学
纳米技术纳米技术
类风湿病学类风湿病学

背景情况:

类风湿性关节炎 (RA) 涉及由低氧和反应性氧物种 (ROS) 驱动的关节炎症.
目前的治疗方法旨在抑制炎症,但经常面临有效性和安全性的挑战.
向巨细胞两极分化是 RA 治疗的一个有希望的策略.

研究的目的:

开发针对性基于的纳米系统 (RuFOMs-FA) 用于类风湿性关节炎 (RA) 治疗.
为了研究RuFOMs-FA在RA治疗中的双阶段巨细胞调节机制.
在大鼠模型中评估RuFOMs-FA在缓解RA症状方面的治疗疗效.

主要方法:

用叶酸修饰 (RuFOMs-FA) 制备装有集群的F127有机二氧化粒.
通过叶酸介导的途径评估光热特性和M1巨的向.
评估纳米剂的酶模仿活动 (catalase和超氧化物脱酶) 用于ROS清理和氧气生产.
使用大鼠RA模型进行体内研究,以评估低氧,炎症和软骨破坏的缓解.

主要成果:

在NIR照射下,RuFOMs-FA显示出高光热转换效率 (55.3%),诱导M1巨细胞死亡.
该纳米系统表现出类似于catalase和类似于超氧化物脱酶的活动,清除ROS并产生氧气.
这一过程促进了M1到M2巨细胞的两极分化,减少了炎症.
在体内,RuFOMs-FA有效地减轻了老鼠RA模型中的缺氧,炎症和软骨破坏.

结论:

RuFOMs-FA通过RA治疗的双阶段巨细胞调节机制起作用.
开发的纳米系统显示出作为一种新的基于贵金属的抗炎剂的潜力,用于RA.
RuFOMs-FA为风湿性关节炎提供了一种有效和安全的治疗候选药物.

关键词:

这是一种抗炎药,是一种抗炎药.有机石英是有机石英的光热的光热系统类风湿性关节炎类风湿性关节炎鲁是的元素之一.

更多相关视频

Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles

Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles

Published on: June 2, 2023

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...